The Problem:

Since the beginning of innovation, institutions have developed ideas and passed them on to industry for design for manufacturing (i.e., translating devices to production): institutional researchers and scientists create innovative solutions across many sectors and patent them; industry seizes the ideas, then translates them to production and pays the institutions a royalty.  This pattern fueled the growth of the national economy, and many of our advanced technologies and medical breakthroughs in the United States were created this way before and through the 20th century.

Innovation and licensing became easier, while translation grew more difficult as technology and science rapidly advanced through the turn of the century. Device testing was more regulated, manufacturing technology was more complex, expensive to implement, and often driven offshore. Only a few large, technically advanced manufacturers remained to deal with shareholders' and investors' demands for high returns. Furthermore, thousands of smaller to mid-sized private manufacturing and distribution companies with lower bandwidth could not access these device translation opportunities.

As the field of manufacturing translation narrowed, institutions developed more intellectual property and produced more ideas needing advanced technology and resources, not understanding how actual device production rules impacted smaller manufacturers' ability to compete in the space. This limited institutional output to only a few ideas a year, cherry-picked by larger manufacturers.

Over-regulation, offshoring, rapid technological advancements, plus disenfranchisement of small manufacturers have created a bottleneck of untapped valuable technology for the healthcare community. Staff reductions at medical institutions and schools due to the financial impact of COVID-19 have only compounded this issue. These institutions are pressured to innovate and bring their ideas to market quicker but with less staffing. Unfortunately, the ideas with both domestic and global value, which are stuck, are either competitive with big tech, or not universally needed enough to get big techs attention. 

The Solution:

Using tens of thousands of hours of experience and powerful software algorithms, we have a systematic way of creating high-level roadmaps for projects that meet a healthy opportunity criterion. Our criterion is based on mechanical or electromechanical FDA Class I or Class II ideas that appeal to small- and medium-sized manufacturers and have the potential for millions in yearly sales.

To help bring these types of devices to market, The Zewski Report offers core services, including cost and timeline estimation, product development guidance, provisional patent preparation, and partnership creation.